The pathological roles of BART miRNAs in nasopharyngeal carcinoma

Journal of Pathology

Volumn 227, Issue 4, 2012, Pages 392-403

  Lo, Angela K F ^a,b,e   Dawson, Christopher W ^b   Jin, Dong Yan ^c   Lo, Kwok Wai ^a,d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

BART; Epstein Barr virus; miRNA; nasopharyngeal carcinoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BAM H1 A RIGHTWARD TRANSCRIPT; BIM PROTEIN; DICER; IMMUNOGLOBULIN A ANTIBODY; KARYOPHERIN; MICRORNA; MICRORNA 122; MICRORNA 9; MIRAVIRSEN; MYC PROTEIN; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL ASSAY; CELL DEATH; CELL IMMORTALIZATION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA METHYLATION; DRUG TARGETING; EPSTEIN BARR VIRUS; EXOSOME; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HEPATITIS C; HOST RESISTANCE; HUMAN; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOPRECIPITATION; INNATE IMMUNITY; INTENSITY MODULATED RADIATION THERAPY; LUNG METASTASIS; MEMORY CELL; MEMORY T LYMPHOCYTE; METASTASIS; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NONHUMAN; OPEN READING FRAME; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEROEPIDEMIOLOGY; TUMOR ASSOCIATED LEUKOCYTE; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REPLICATION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, INNATE; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; RNA, VIRAL; VIRAL PROTEINS;

EID: 84863724987     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4025     Document Type: Review

References (117)

1. Yu MC, Yuan JM,. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-429.
2. Marks JE, Phillips JL, Menck HR,. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998; 83: 582-588.
3. Tao Q, Young LS, Woodman CB, et al., Epstein-Barr virus (EBV) and its associated human cancersâ€"genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006; 11: 2672-2713.
4. Raab-Traub N,. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431-441.
5. Feng BJ, Huang W, Shugart YY, et al., Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31: 395-399.
6. Bei JX, Li Y, Jia WH, et al., A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010; 42: 599-603.
7. Xiong W, Zeng ZY, Xia JH, et al., A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004; 64: 1972-1974.
8. Lo KW, Teo PM, Hui AB, et al., High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 2000; 60: 3348-3353.
9. Hui AB, Lo KW, Leung SF, et al., Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 1999; 82: 498-503.
10. Lo KW, Cheung ST, Leung SF, et al., Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996; 56: 2721-2725.
11. Lo KW, Kwong J, Hui AB, et al., High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 3877-3881.
12. Kwong J, Lo KW, To KF, et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002; 8: 131-137.
13. Vokes EE, Liebowitz DN, Weichselbaum RR,. Nasopharyngeal carcinoma. Lancet 1997; 350: 1087-1091.
14. Hsu MM, Tu SM,. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52: 362-368.
15. Lee N, Xia P, Quivey JM, et al., Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22.
16. Kam MK, Teo PM, Chau RM, et al., Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004; 60: 1440-1450.
17. Hui EP, Leung SF, Au JS, et al., Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004; 101: 300-306.
18. Henle W, Henle G, Ho HC, et al., Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 1970; 44: 225-231.
19. de Schryver A, Friberg S Jr, Klein G, et al., Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol 1969; 5: 443-459.
20. zur HH, Schulte-Holthausen H, Klein G, et al., EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228: 1056-1058.
21. Raab-Traub N, Flynn K,. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47: 883-889.
22. Lo KW, To KF, Huang DP,. Focus on nasopharyngeal carcinoma. Cancer Cell 2004; 5: 423-428.
23. Rickinson AB, Kieff E,. Epstein-Barr virus. In Field's Virology, Fields BN, Knipe DM, Howley PM, et al,. (eds). Lippincott Williams & Wilkins: Philadelphia, PA, 2007; 2655-2700.
24. Cullen BR,. Viruses and microRNAs. Nat Genet 2006; 38: S25-30.
25. Smith PR, de Jesus O, Turner D, et al., Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol 2000; 74: 3082-3092.
26. Al Mozaini M, Bodelon G, Karstegl CE, et al., Epstein-Barr virus BART gene expression. J Gen Virol 2009; 90: 307-316.
27. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
28. Pfeffer S, Zavolan M, Grasser FA, et al., Identification of virus-encoded microRNAs. Science 2004; 304: 734-736.
29. Zhu JY, Pfuhl T, Motsch N, et al., Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol 2009; 83: 3333-3341.
30. Lung RW, Tong JH, Sung YM, et al., Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009; 11: 1174-1184.
31. Chen SJ, Chen GH, Chen YH, et al., Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. PLoS One 2010; 5: e12745.
32. Cai X, Schafer A, Lu S, et al., Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006; 2: e23.
33. 3-herpesviruses. RNA 2006; 12: 733-750.
34. Lo AK, To KF, Lo KW, et al., Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 2007; 104: 16164-16169.
35. Kim dN, Chae HS, Oh ST, et al., Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 2007; 81: 1033-1036.
36. Imig J, Motsch N, Zhu JY, et al., microRNA profiling in Epstein-Barr virus-associated B cell lymphoma. Nucleic Acids Res 2011; 39: 1880-1893.
37. Qiu J, Cosmopoulos K, Pegtel M, et al., A novel persistence-associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 2011; 7: e1002193.
38. Cosmopoulos K, Pegtel M, Hawkins J, et al., Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 2009; 83: 2357-2367.
39. Wong AM, Kong KL, Tsang JW, et al., Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2012; 118: 698-710.
40. Iizasa H, Wulff BE, Alla NR, et al., Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 2010; 285: 33358-33370.
41. Seto E, Moosmann A, Gromminger S, et al., MicroRNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog 2010; 6: e1001063.
42. Spruck CH, III, Tsai YC, Huang DP, et al., Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992; 52: 4787-4790.
43. Sun Y, Hegamyer G, Cheng YJ, et al., An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1992; 89: 6516-6520.
44. Murono S, Yoshizaki T, Park CS, et al., Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology 1999; 34: 432-438.
45. Niedobitek G, Agathanggelou A, Barber P, et al., p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 1993; 170: 457-461.
46. Chow LW, Khoo US, Yuen AP, et al., Expression of p53 in recurrent nodal metastasis from nasopharyngeal carcinoma (NPC). Eur J Surg Oncol 1997; 23: 415-418.
47. Choy EY, Siu KL, Kok KH, et al., An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008; 205: 2551-2560.
48. Marquitz AR, Mathur A, Nam CS, et al., The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 2011; 412: 392-400.
49. 3-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 2010; 7: 324-334.
50. Bellot G, Cartron PF, Er E, et al., TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ 2007; 14: 785-794.
51. Ott M, Norberg E, Zhivotovsky B, et al., Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ 2009; 16: 1075-1082.
52. Young LS, Rickinson AB,. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
53. Lin X, Gudgeon NH, Hui EP, et al., CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 2008; 57: 963-975.
54. Lee SP, Chan AT, Cheung ST, et al., CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000; 165: 573-582.
55. Whitney BM, Chan AT, Rickinson AB, et al., Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 2002; 67: 359-363.
56. Li J, Zeng XH, Mo HY, et al., Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One 2007; 2: e1122.
57. Zheng Y, Cao KY, Ng SP, et al., Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma. Cancer Sci 2006; 97: 912-919.
58. + T cells. Cancer Res 1999; 59: 1599-1605.
59. Ferradini L, Miescher S, Stoeck M, et al., Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma. Int J Cancer 1991; 47: 362-370.
60. Nachmani D, Stern-Ginossar N, Sarid R, et al., Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009; 5: 376-385.
61. Lisnic VJ, Krmpotic A, Jonjic S,. Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 2010; 13: 530-539.
62. Diefenbach A, Jamieson AM, Liu SD, et al., Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-126.
63. Jakel S, Albig W, Kutay U, et al., The importin-β/importin 7 heterodimer is a functional nuclear import receptor for histone H1. EMBO J 1999; 18: 2411-2423.
64. Yang IV, Wade CM, Kang HM, et al., Identification of novel genes that mediate innate immunity using inbred mice. Genetics 2009; 183: 1535-1544.
65. Abramson J, Giraud M, Benoist C, et al., Aire's partners in the molecular control of immunological tolerance. Cell 2010; 140: 123-135.
66. Ishiguro K, Ando T, Maeda O, et al., Acetate inhibits NFAT activation in T cells via importin β1 interference. Eur J Immunol 2007; 37: 2309-2316.
67. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al., Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010; 107: 6328-6333.
68. Gourzones C, Gelin A, Bombik I, et al., Extracellular release and blood diffusion of BART viral microRNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virol J 2010; 7: 271.
69. Barth S, Pfuhl T, Mamiani A, et al., Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008; 36: 666-675.
70. Kieff E, Rickinson AB,. Epstein-Barr virus and its replication. In Field's Virology, Fields BN, Knipe DM, Howley PM, et al,. (eds). Lippincott Williams & Wilkins: Philadelphia, PA, 2007; 2603-2654.
71. Brooks L, Yao QY, Rickinson AB, et al., Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66: 2689-2697.
72. Heussinger N, Buttner M, Ott G, et al., Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004; 203: 696-699.
73. Allen MD, Young LS, Dawson CW,. The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 2005; 79: 1789-1802.
74. Fotheringham JA, Mazzucca S, Raab-Traub N,. Epstein-Barr virus latent membrane protein-2A-induced Î́Np63α expression is associated with impaired epithelial-cell differentiation. Oncogene 2010; 29: 4287-4296.
75. Fukuda M, Longnecker R,. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt pathway. J Virol 2007; 81: 9299-9306.
76. Pegtel DM, Subramanian A, Sheen TS, et al., Epstein-Barr virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol 2005; 79: 15430-15442.
77. Hislop AD, Taylor GS, Sauce D, et al., Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587-617.
78. + T cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 2002; 99: 93-99.
79. Straathof KC, Leen AM, Buza EL, et al., Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 2005; 175: 4137-4147.
80. Tao Q, Chan AT,. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9: 1-24.
81. Lo AK, Liu Y, Wang XH, et al., Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein-Barr virus-encoded latent membrane protein 1. Lab Invest 2003; 83: 697-709.
82. Lo AK, Huang DP, Lo KW, et al., Phenotypic alterations induced by the Hong Kong-prevalent Epstein-Barr virus-encoded LMP1 variant (2117-LMP1) in nasopharyngeal epithelial cells. Int J Cancer 2004; 109: 919-925.
83. Tsao SW, Tramoutanis G, Dawson CW, et al., The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 473-487.
84. Eliopoulos AG, Dawson CW, Mosialos G, et al., CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996; 13: 2243-2254.
85. Kawanishi M,. The Epstein-Barr virus latent membrane protein 1 (LMP1) enhances TNFα-induced apoptosis of intestine 407 epithelial cells: the role of LMP1 C-terminal activation regions 1 and 2. Virology 2000; 270: 258-266.
86. Liu Y, Wang X, Lo AK, et al., Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. J Med Virol 2002; 66: 63-69.
87. Lu JJ, Chen JY, Hsu TY, et al., Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J Gen Virol 1996; 77 (8): 1883-1892.
88. Zhang X, Hu L, Fadeel B, et al., Apoptosis modulation of Epstein-Barr virus-encoded latent membrane protein 1 in the epithelial cell line HeLa is stimulus-dependent. Virology 2002; 304: 330-341.
89. Dirmeier U, Hoffmann R, Kilger E, et al., Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005; 24: 1711-1717.
90. Liu MT, Chen YR, Chen SC, et al., Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004; 23: 2531-2539.
91. Stevenson D, Charalambous C, Wilson JB,. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGFα concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res 2005; 65: 8826-8835.
92. Hannigan A, Wilson JB,. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol Cancer 2010; 9: 184.
93. Ramakrishnan R, Donahue H, Garcia D, et al., Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas. PLoS One 2011; 6: e27271.
94. Simons M, Raposo G,. Exosomesâ€"vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009; 21: 575-581.
95. Zomer A, Vendrig T, Hopmans ES, et al., Exosomes: fit to deliver small RNA. Commun Integr Biol 2010; 3: 447-450.
96. Meckes DG Jr, Shair KH, Marquitz AR, et al., Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA 2010; 107: 20370-20375.
97. Garzon R, Marcucci G, Croce CM,. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
98. Esau C, Davis S, Murray SF, et al., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
99. Jopling CL, Yi M, Lancaster AM, et al., Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309: 1577-1581.
100. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al., Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
101. Ebert MS, Sharp PA,. MicroRNA sponges: progress and possibilities. RNA 2010; 16: 2043-2050.
102. Ma L, Young J, Prabhala H, et al., miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
103. Choy EY, Kok KH, Tsao SW, et al., Utility of Epstein-Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs. Gene Ther 2008; 15: 191-202.
104. Sadler RH, Raab-Traub N,. Structural analyses of the Epstein-Barr virus BamHI-A transcripts. J Virol 1995; 69: 1132-1141.
105. Chen H, Huang J, Wu FY, et al., Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. J Virol 2005; 79: 1724-1733.
106. Edwards RH, Marquitz AR, Raab-Traub N,. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 2008; 82: 9094-9106.
107. Kim dN, Song YJ, Lee SK,. The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines. Exp Mol Med 2011; 43: 401-410.
108. de Jesus O, Smith PR, Spender LC, et al., Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J Gen Virol 2003; 84: 1443-1450.
109. Esteller M,. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
110. Barnes BJ, Moore PA, Pitha PM,. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon-α genes. J Biol Chem 2001; 276: 23382-23390.
111. Zhang L, Pagano JS,. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol Cell Biol 1997; 17: 5748-5757.
112. Martin HJ, Lee JM, Walls D, et al., Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol 2007; 81: 9748-9758.
113. Zhao Y, Xu D, Jiang Y, et al., Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes. PLoS One 2010; 5: e9459.
114. Ning S, Pagano JS, Barber GN,. IRF7: activation, regulation, modification and function. Genes Immun 2011; 12: 399-414.
115. Buehrlen M, Zwaan CM, Granzen B, et al., Multimodal treatment, including interferon-β, of nasopharyngeal carcinoma in children and young adults. Cancer 2012.
116. Wolff HA, Rodel RMW, Gunawan B, et al., Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-β in undifferentiated carcinomas. J Cancer Res Clin Oncol 2010; 136: 89-97.
117. Ning S, Huye LE, Pagano JS,. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J Virol 2005; 79: 11671-11676.